Condition
Tyrosinemia, Type I
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed3
Enrolling By Invitation1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05687474Completed
Baby Detect : Genomic Newborn Screening
NCT03655223Enrolling By Invitation
Early Check: Expanded Screening in Newborns
NCT06298292Not Yet RecruitingPrimary
Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies
NCT04196959Not ApplicableCompleted
Evaluation of TYR Sphere
NCT00004333Phase 2CompletedPrimary
Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I
Showing all 5 trials